PubMed for id: 1646561

Year	Number of Results
1977	1
1980	1
1981	1
1985	1
1986	1
1987	2
1988	3
1989	4
1990	2
1991	4
1992	6
1993	1
1994	6
1995	1
1996	6
1997	7
1998	5
1999	7
2000	11
2001	11
2002	10
2003	21
2004	19
2005	15
2006	17
2007	13
2008	19
2009	22
2010	23
2011	23
2012	21
2013	15
2014	15
2015	7
2016	16
2017	9
2018	7
2019	12
2020	9
2021	8
2022	8
2023	4
2024	1

1

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients.

Li Y, Xu W, Fei Y, Wu M, Yuan J, Qiu L, Zhang Y, Chen G, Cheng Y, Cao Y, Zhou S. Li Y, et al. Discov Oncol. 2023 Aug 23;14(1):154. doi: 10.1007/s12672-023-00751-x. Discov Oncol. 2023. PMID: 37612579 Free PMC article.

2

scRNA-seq and proteomics reveal the distinction of M2-like macrophages between primary and recurrent malignant glioma and its critical role in the recurrence.

You G, Zheng Z, Huang Y, Liu G, Luo W, Huang J, Zhuo L, Tang B, Liu S, Lin C. You G, et al. CNS Neurosci Ther. 2023 Nov;29(11):3391-3405. doi: 10.1111/cns.14269. Epub 2023 May 17. CNS Neurosci Ther. 2023. PMID: 37194413 Free PMC article.

3

Short- and long-term efficacy of sustained-release chemotherapy in tumor bed interstitium combined with surgical resection for recurrent malignant glioma.

Wang L, Wang Z, Liang Z, Li G, Duan S, Xi Y. Wang L, et al. Am J Transl Res. 2022 Aug 15;14(8):5669-5676. eCollection 2022. Am J Transl Res. 2022. PMID: 36105035 Free PMC article.

4

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.

Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. Groot J, et al. CNS Oncol. 2022 Jun 1;11(2):CNS87. doi: 10.2217/cns-2022-0005. Epub 2022 May 16. CNS Oncol. 2022. PMID: 35575067 Free PMC article. Clinical Trial.

5

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.

Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI. Furuse M, et al. Jpn J Clin Oncol. 2022 May 5;52(5):433-440. doi: 10.1093/jjco/hyac004. Jpn J Clin Oncol. 2022. PMID: 35079791

6

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

Reardon DA, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams JH, Li R, Taylor CT, Lassman AB. Reardon DA, et al. Invest New Drugs. 2020 Dec;38(6):1784-1795. doi: 10.1007/s10637-020-00950-1. Epub 2020 May 20. Invest New Drugs. 2020. PMID: 32436060 Clinical Trial.

7

Study protocol of a Phase I/IIa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma.

Kurozumi K, Fujii K, Shimazu Y, Tomita Y, Sasaki T, Yasuhara T, Hishikawa T, Kameda M, Kumon H, Date I. Kurozumi K, et al. Future Oncol. 2020 Feb;16(6):151-159. doi: 10.2217/fon-2019-0743. Epub 2020 Jan 24. Future Oncol. 2020. PMID: 31973596

8

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW. Zeiner PS, et al. J Clin Med. 2019 Nov 21;8(12):2031. doi: 10.3390/jcm8122031. J Clin Med. 2019. PMID: 31766326 Free PMC article.

9

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII.

Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Rosenthal M, et al. Cancer Chemother Pharmacol. 2019 Aug;84(2):327-336. doi: 10.1007/s00280-019-03879-2. Epub 2019 Jun 1. Cancer Chemother Pharmacol. 2019. PMID: 31154523 Clinical Trial.

10

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.

Philbrick BD, Adamson DC. Philbrick BD, et al. Expert Opin Investig Drugs. 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. Expert Opin Investig Drugs. 2019. PMID: 30676111 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

361 results

Results by year